Cardiol Therapeutics (TSE:CRDL) Trading 1.6% Higher – Here’s Why

Cardiol Therapeutics Inc. (TSE:CRDL)’s share price traded up 1.6% during trading on Thursday . The company traded as high as C$1.94 and last traded at C$1.93. 130,571 shares were traded during trading, an increase of 33% from the average session volume of 98,254 shares. The stock had previously closed at C$1.90.

Cardiol Therapeutics Trading Up 3.1%

The company has a current ratio of 4.39, a quick ratio of 6.84 and a debt-to-equity ratio of 0.48. The stock has a 50 day simple moving average of C$1.60 and a 200-day simple moving average of C$1.61. The firm has a market cap of C$229.39 million, a P/E ratio of -5.10 and a beta of 0.27.

Cardiol Therapeutics (TSE:CRDL) last posted its earnings results on Monday, May 11th. The company reported C($0.10) EPS for the quarter. On average, equities research analysts expect that Cardiol Therapeutics Inc. will post -0.49 EPS for the current fiscal year.

About Cardiol Therapeutics

Cardiol Therapeutics Inc ( NASDAQ: CRDL ) ( TSX: CRDL ) is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The Company’s lead small-molecule drug candidate, CardiolRx¿, modulates inflammasome pathway activation, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure. The MAVERIC Program is evaluating CardiolRx¿ for the treatment of recurrent pericarditis, an inflammatory disease of the pericardium associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, which can lead to physical limitations, reduced quality of life, emergency department visits, and hospitalizations.